Company Overview and News

 
Virtus Health Ltd. ADR 2018 Q2 - Results - Earnings Call Slides

2018-02-20 seekingalpha
The following slide deck was published by Virtus Health Ltd. ADR in conjunction with their 2018 Q2 earnings call.
Upvote Downvote

 
Bioethicists raise alarm about conflicts of interest in Australia's IVF industry

2017-11-01 theage.com.au
The IVF industry has been accused of increasingly placing profits over patients, with a new study suggesting that some doctors are offering women more treatment cycles than appropriate or necessary.
Upvote Downvote

 
Bioethicists raise alarm about conflicts of interest in Australia's IVF industry

2017-11-01 smh.com.au
The IVF industry has been accused of increasingly placing profits over patients, with a new study suggesting that some doctors are offering women more treatment cycles than appropriate or necessary.
Upvote Downvote

 
Monash IVF, Virtus Health shares flounder

2017-10-09 theage.com.au
Despite one of the clearest themes in Australian investing, the business of in-vitro fertilisation has not delivered the stellar returns many shareholders may have been expecting.
Upvote Downvote

 
Monash IVF, Virtus Health shares flounder

2017-10-09 smh.com.au
Despite one of the clearest themes in Australian investing, the business of in-vitro fertilisation has not delivered the stellar returns many shareholders may have been expecting.
Upvote Downvote

 
Fertility business booms in China

2017-07-16 nzherald.co.nz
On a recent afternoon, a visitor from northern China took a smoke break outside the Beijing Perfect Family Hospital. Cigarettes were one reason he had come to the capital: he reckons his nicotine habit played a part in damaging his fertility.
Upvote Downvote

 
After relaxing one-child policy, China faces a new challenge — fertility problems

2017-07-16 thestar
Factors like lower sperm counts, later pregnancies and other health barriers are making it harder for many in China to get pregnant.
Upvote Downvote

 
Harvey Norman hit hard as ASX edges lower

2017-03-20 theage.com.au
The S&P/ASX200 index remains unable to maintain gains above the 5800 level, with broad-based losses across most sectors erasing last week's positive moment.
Upvote Downvote

 
Harvey Norman hit hard as ASX edges lower

2017-03-20 smh.com.au
The S&P/ASX200 index remains unable to maintain gains above the 5800 level, with broad-based losses across most sectors erasing last week's positive moment.
Upvote Downvote

 
Virtus H1FY17 Results Impacted By Weak Domestic Demand

2017-02-21 devicespace
Sydney, Australia - Virtus Health, (“Virtus”, ASX: VRT) Australia and Ireland’s largest Assisted Reproductive Services (ARS) provider, today reports its financial results for the half year ended 31 December 2016.
Upvote Downvote

 
Virtus profit hit as IVF demand falls

2017-02-21 theage.com.au
One of Australia's largest IVF providers has suffered an almost 18 per cent fall in first-half profit as demand for IVF treatments in Australia sinks.
Upvote Downvote

 
Virtus profit hit as IVF demand falls

2017-02-21 smh.com.au
One of Australia's largest IVF providers has suffered an almost 18 per cent fall in first-half profit as demand for IVF treatments in Australia sinks.
Upvote Downvote

 
ASX lifts as Fortescue hits six-year high

2017-02-01 theage.com.au
Mining and energy stocks gave the local sharemarket a lift on Wednesday, but investors remain wary of the Donald Trump administration's rapid onslaught of policy changes and commentary around currencies and trade. 
Upvote Downvote

 
ASX lifts as Fortescue hits six-year high

2017-02-01 smh.com.au
Mining and energy stocks gave the local sharemarket a lift on Wednesday, but investors remain wary of the Donald Trump administration's rapid onslaught of policy changes and commentary around currencies and trade. 
Upvote Downvote

 
Australian market to open higher

2017-01-31 ntnews.com.au
THE Australian market looks set to open higher despite falls on US markets for the second straight session.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...